Georgia Anti-Kickback Statute Guide (2026)

title: Georgia Anti-Kickback Statute (Section 1128B): A Complete Guide subtitle: The federal Anti-Kickback Statute (AKS), the 42 CFR 1001.952 safe harbors, OIG advisory opinions and the Self-Disclosure Protocol, the Beneficiary Inducement CMP, EKRA, and how Georgia hospitals, physician practices, pharmacies, and healthcare entities structure compliant financial relationships.

By Brevy Care Team · Last verified May 13, 2026

This guide explains the federal authorities (Section 1128B(b) of the Social Security Act, the 42 CFR 1001.952 safe harbors, the OIG advisory opinion program, the Self-Disclosure Protocol, the Beneficiary Inducement CMP at Section 1128A(a)(5)), the knowing-and-willful intent standard, the One Purpose Rule established by United States v. Greber, the breadth of the "remuneration" concept, the OIG enforcement framework (advisory opinions, SDP, Corporate Integrity Agreements, Special Fraud Alerts), the Eliminating Kickbacks in Recovery Act (EKRA), the distinction and coordination with the strict liability Stark Law, the Georgia enforcement landscape (U.S. Attorney's Offices, OIG Atlanta, Georgia Medicaid Fraud Control Unit), the major Georgia health systems and AKS compliance considerations, and the practical compliance steps that Georgia hospitals, physician practices, pharmacies, and healthcare entities should take.

The Federal Statutory Framework

Section 1128B(b) of the Social Security Act: The Original 1977 AKS

The Anti-Kickback Statute was first enacted as part of the Medicare-Medicaid Anti-Fraud and Abuse Amendments of 1977 (Public Law 95-142). The 1977 enactment elevated kickback violations from misdemeanors to felonies and established the basic prohibition framework. The statute was codified at Section 1128B(b) of the Social Security Act (42 U.S.C. 1320a-7b(b)).

The 1987 Patient and Program Protection Act Expansion

The Medicare and Medicaid Patient and Program Protection Act of 1987 (Public Law 100-93) substantially expanded the AKS framework. The 1987 amendments:

• Authorized the Secretary of Health and Human Services to exclude individuals and entities convicted of AKS violations from participation in Medicare and other federal healthcare programs.
• Required the Secretary to specify safe harbor arrangements that would not be subject to criminal prosecution under the AKS.
• Established the framework for the OIG to administer the AKS through both enforcement and regulatory guidance.

The 2010 ACA Modifications

The Patient Protection and Affordable Care Act of 2010 (Public Law 111-148) included several important AKS modifications:

Section 6402(f) Per Se False Claims Act Liability: Section 6402(f) amended the False Claims Act to provide that claims submitted in violation of the AKS constitute false claims for purposes of the False Claims Act. This eliminates the need for prosecutors and qui tam relators to separately establish a "false statement" connection, streamlining FCA cases based on AKS violations.

Section 6402(h) Clarification of AKS Intent Standard: Section 6402(h) added Section 1128B(h) to the Social Security Act, clarifying that AKS violations do not require proof that the defendant knew the specific statute or specifically intended to violate it. The defendant must have acted "knowingly and willfully" but does not need to know that the conduct specifically violates the AKS.

Mandatory Compliance Programs: Section 6401 required certain healthcare providers to establish compliance programs, and Section 6102 required nursing homes to have compliance and ethics programs.

The 2018 SUPPORT Act Enhancement

The Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) of 2018 (Public Law 115-271) enhanced AKS penalties, increasing maximum criminal imprisonment and fines per violation under Section 1128B(b). Verify current statutory maximums in the U.S. Code as in effect today, since these figures have been amended.

Section 220 of the SUPPORT Act also established the Eliminating Kickbacks in Recovery Act (EKRA), extending AKS-like prohibitions to substance use disorder treatment.

The Core AKS Prohibitions

Section 1128B(b)(1): Soliciting or Receiving Remuneration

Section 1128B(b)(1) makes it a felony for any person to knowingly and willfully solicit or receive any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for:

• Referring an individual for the furnishing of any item or service for which payment may be made under a federal healthcare program.
• Arranging for or recommending the purchasing, leasing, or ordering of any good, facility, service, or item for which payment may be made under a federal healthcare program.

Section 1128B(b)(2): Offering or Paying Remuneration

Section 1128B(b)(2) makes it a felony for any person to knowingly and willfully offer or pay any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to:

• Induce a person to refer an individual for the furnishing of any item or service for which payment may be made under a federal healthcare program.
• Induce a person to purchase, lease, or order any good, facility, service, or item for which payment may be made under a federal healthcare program.

Elements of a Violation

A criminal AKS violation under Section 1128B(b) requires proof of:

1. Knowing and willful conduct: The defendant acted with knowledge that the conduct was unlawful, though does not need to know the specific statute violated.
2. Solicitation, receipt, offer, or payment: One of the four covered conduct categories.
3. Remuneration: Any form of consideration, broadly construed.
4. Intent to induce or reward: At least one purpose of the remuneration was to induce referrals or generate business (One Purpose Rule).
5. Federal healthcare program reimbursement: The referred services or items are reimbursable under a federal healthcare program.

Penalties Under the AKS

Criminal Penalties (Section 1128B(b))

AKS criminal violations carry significant imprisonment exposure and substantial criminal fines per violation, as amended by the SUPPORT Act of 2018. Both individual and entity defendants are subject to criminal prosecution. Confirm current statutory maximums in 42 U.S.C. 1320a-7b(b) as in effect today.

Civil Monetary Penalties

Section 1128A(a)(7) of the Social Security Act establishes civil monetary penalties for AKS violations, including a substantial per-violation penalty plus a multiplier of the amount of remuneration involved. CMP figures are subject to annual inflation adjustment under the Federal Civil Penalties Inflation Adjustment Act; consult the current OIG CMP adjustment notice for the dollar amounts in effect this year.

Exclusion from Federal Healthcare Programs

Section 1128(a)(1) of the Social Security Act provides for mandatory exclusion from Medicare and other federal healthcare programs for AKS conviction. Section 1128(b)(7) provides for permissive exclusion in additional circumstances. Exclusion has dramatic financial consequences for healthcare entities and individuals.

False Claims Act Liability

After ACA Section 6402(f), AKS violations constitute per se false claims under the federal False Claims Act (31 U.S.C. 3729-3733), which carries treble damages and per-claim civil penalties indexed annually for inflation. Qui tam relators may file FCA lawsuits on behalf of the government and share in any recovery; consult the current FCA statute and the most recent DOJ civil-penalty inflation adjustment notice for the current per-claim range and relator-share percentages.

State Law Penalties

Many states have parallel anti-kickback laws and Medicaid False Claims Acts. Georgia's Medicaid fraud framework includes provisions that parallel federal AKS coverage. The Georgia Bureau of Investigation operates the Medicaid Fraud Control Unit, which investigates and prosecutes Medicaid fraud and abuse.

The Knowing and Willful Standard

The AKS requires that the defendant act knowingly and willfully. The Affordable Care Act's Section 1128B(h) clarification (effective March 23, 2010) explicitly states that the defendant does not need to know that conduct specifically violates the AKS, only that the defendant acted with intent to do something the law prohibits.

Pre-ACA Intent Debate

Before the 2010 ACA clarification, courts had split on the intent standard. Some courts required proof that the defendant specifically knew of the AKS and intended to violate it; others required only general intent. The ACA codified the lower intent standard, making AKS prosecutions easier than under the older specific-intent interpretation.

Practical Implications

The knowing-and-willful standard means:

• Pure mistakes or technical errors without intent do not violate the AKS.
• Reckless conduct may not satisfy the intent standard.
• Deliberate ignorance (willful blindness) can satisfy the intent standard.
• Intent can be inferred from circumstantial evidence (the structure of the arrangement, deviations from fair market value, lack of business purpose).

The One Purpose Rule

The One Purpose Rule, established by the Third Circuit in United States v. Greber (1985) and adopted by most other federal circuits, holds that if even one purpose of remuneration is to induce or reward referrals, the AKS is violated. The remuneration does not need to be the sole or primary purpose.

Greber Facts

In Greber, a physician provided cardiac monitoring services and paid referring physicians a percentage of Medicare payments. The Third Circuit held that even though the physicians performed legitimate services warranting payment, if one purpose of the payment was to induce referrals, the AKS was violated.

Subsequent Adoption

The One Purpose Rule has been adopted by most federal circuits. Some circuits have used slightly different formulations (e.g., "any purpose" or "a purpose"), but the substantive rule is similar.

Practical Compliance Implications

The One Purpose Rule means that arrangements must be carefully structured to remove any inference that referrals are a purpose of remuneration. This often requires:

• Clear separation of payment for services from referral relationships.
• Fair market value documentation.
• Commercial reasonableness analysis.
• Written agreements specifying services and consideration.
• Absence of referral-volume-based metrics in compensation.

The Breadth of "Remuneration"

The term remuneration under the AKS is interpreted very broadly to include any form of value transfer, regardless of form, label, or structure.

Examples of Remuneration

• Cash payments
• Checks and wire transfers
• Stock or other equity interests
• Forgiveness of debt
• Free or below-market services
• Free or below-market equipment
• Above-market discounts
• Royalties not commensurate with intellectual property contributions
• Speaker fees and honoraria
• Consulting fees exceeding fair market value
• Meals and entertainment beyond nominal limits
• Travel and lodging
• Education or training benefits beyond required CME
• Research grants without proper structure
• Marketing assistance
• Office space or staffing assistance
• Loans on favorable terms
• Charitable contributions in lieu of compensation

Direct and Indirect Remuneration

The AKS applies to direct remuneration (payment from referral source to referring physician) and indirect remuneration (payment through intermediaries or to family members or related entities). The breadth of indirect remuneration coverage means complex structures often require detailed analysis.

In-Cash and In-Kind Remuneration

The AKS covers both monetary and non-monetary remuneration. In-kind benefits are valued at their fair market value for purposes of AKS analysis.

The 42 CFR 1001.952 Safe Harbors

The OIG has promulgated regulatory safe harbors at 42 CFR 1001.952 that provide immunity from AKS prosecution for arrangements that meet specific technical requirements. Safe harbor compliance is voluntary; failure to satisfy all the technical requirements does not automatically result in an AKS violation, but it does mean the arrangement is analyzed under the intent-based standard.

Original 1991 Safe Harbors

The OIG issued the original safe harbors on July 29, 1991. Key 1991 safe harbors include:

42 CFR 1001.952(a) Investment Interests: Provides protection for returns on investment interests (e.g., dividends, distributions) when the investment meets specific requirements regarding the nature of investors, investment terms, and absence of referral-based returns.

42 CFR 1001.952(b) Space Rental: Protects rental of office space when:

• Written lease signed by parties.
• Specified premises covered.
• Lease term at least one year.
• Aggregate space rented does not exceed reasonable and necessary needs.
• Aggregate rental charge is set in advance, consistent with fair market value, and not determined by referral volume or value.
• Charge is commercially reasonable absent referrals.

42 CFR 1001.952(c) Equipment Rental: Parallels space rental safe harbor, applied to equipment.

42 CFR 1001.952(d) Personal Services and Management Contracts: Protects personal service and management arrangements when:

• Written agreement signed by parties.
• Specifies services covered.
• Aggregate services do not exceed reasonable and necessary needs.
• Term at least one year.
• Aggregate compensation set in advance, consistent with FMV, and not determined by referral volume or value.
• Services do not involve illegal activities.

42 CFR 1001.952(e) Sale of Practice: Protects sale of physician practice when seller stops practicing within one year and the buyer is a hospital or other entity not in a position to refer.

42 CFR 1001.952(f) Referral Services: Protects referral services (e.g., physician finder services) when the fee structure meets specific requirements (cost-based or fixed fee, no referral-volume basis).

42 CFR 1001.952(g) Warranties: Protects manufacturer or supplier warranties on items, when specific conditions are met.

42 CFR 1001.952(h) Discounts: Protects discounts when specific conditions are met (price reductions known and disclosed, properly reflected in cost reporting, etc.).

42 CFR 1001.952(i) Employees: Provides broad protection for bona fide employment relationships. Employee compensation generally does not violate AKS provided the employment is genuine. The employee safe harbor is one of the most important AKS protections, allowing hospitals to employ physicians and other healthcare providers without AKS exposure for employment compensation.

42 CFR 1001.952(j) Group Purchasing Organizations: Protects GPO administrative fees when specific conditions are met.

42 CFR 1001.952(k) Waiver of Beneficiary Coinsurance and Deductibles: Protects certain limited waivers of beneficiary cost-sharing, primarily for hospital inpatient services under specific conditions.

Additions Through the 1990s and 2000s

Numerous safe harbors were added through subsequent rulemaking, including:

42 CFR 1001.952(l) MA Bona Fide Activities: Protects increased coverage, reduced cost-sharing, or reduced premiums offered by MA organizations to enrollees.

42 CFR 1001.952(m) Practitioner Recruitment: Protects hospital recruitment of physicians to underserved areas, with specific requirements.

42 CFR 1001.952(n) Obstetrical Malpractice Insurance Subsidies: Protects hospital subsidies for obstetrical malpractice insurance, with specific requirements.

42 CFR 1001.952(o) Investments in Group Practices: Protects certain investments in group practices.

42 CFR 1001.952(q) Ambulatory Surgical Centers: Multiple sub-categories protecting various ASC investment and operational arrangements.

42 CFR 1001.952(y) EHR Items and Services: Protects EHR donation arrangements, paralleling the Stark Law EHR donation exception. The safe harbor requires the recipient to pay a meaningful share of the donor's cost (confirm the current percentage in the current text of 42 CFR 1001.952(y)), and interoperability and anti-information-blocking requirements apply.

The 2020 Modernization Rule

The OIG's November 2020 final rule (effective primarily January 19, 2021) substantially modernized the AKS safe harbors in coordination with CMS's parallel Stark Law modernization. Confirm the exact Federal Register citation in the current eCFR/Federal Register record. The 2020 rule added several new safe harbors focused on value-based care:

42 CFR 1001.952(ee) Value-Based Arrangements With Full Financial Risk: For value-based enterprises where participants have assumed full financial risk for cost and quality of items and services for the target patient population. This is the most flexible value-based safe harbor.

42 CFR 1001.952(ff) Value-Based Arrangements With Substantial Downside Financial Risk: For VBEs where participants assume substantial downside risk (specific threshold). Moderate flexibility.

42 CFR 1001.952(gg) Care Coordination Arrangements: For value-based arrangements without risk assumption, with more detailed compliance requirements covering care coordination activities, in-kind remuneration limits, and other specifics.

42 CFR 1001.952(hh) Patient Engagement and Support: Protects in-kind tools, supports, and other remuneration provided to patients by VBE participants to support patient engagement in value-based care.

42 CFR 1001.952(ii) CMS-Sponsored Model Arrangements: Protects arrangements that meet the requirements of CMS-sponsored model programs (ACO, bundled payment, etc.).

42 CFR 1001.952(jj) Cybersecurity Technology and Services: Protects donation of cybersecurity technology and services between healthcare entities to address growing cybersecurity threats in healthcare.

42 CFR 1001.952(kk) ACO Beneficiary Incentives: Protects beneficiary incentive payments made by ACOs participating in eligible ACO programs.

Safe Harbor Compliance is Voluntary

A key principle of the AKS framework is that safe harbor compliance is voluntary, not mandatory. Failure to satisfy all the technical requirements of a safe harbor does not automatically result in an AKS violation.

Intent-Based Analysis Outside Safe Harbors

When an arrangement does not meet a safe harbor, the OIG and federal courts analyze it under the intent-based AKS standard. Factors considered include:

• The structure of the arrangement.
• Whether the remuneration represents fair market value for the services or items provided.
• Whether the arrangement has a commercial rationale beyond inducing referrals.
• The parties' history and referral relationships.
• The relationship of compensation to referrals.
• The presence of risk factors identified in OIG Special Fraud Alerts.

OIG Advisory Opinions Outside Safe Harbors

The OIG advisory opinion program provides a mechanism for parties to seek OIG analysis of specific arrangements that do not fit precisely within a safe harbor. Many advisory opinions analyze arrangements that fall outside safe harbors and conclude that the OIG would not impose sanctions, often based on specific protections built into the arrangement.

The OIG Advisory Opinion Program

Background

The OIG Advisory Opinion Program was established by Section 205 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA, Public Law 104-191) and is codified at 42 CFR Part 1008. The program allows parties to request OIG opinions on specific arrangements they have entered into or are contemplating.

Program Structure

• The OIG issues legally binding advisory opinions on specific arrangements.
• Opinions are limited to the facts presented; OIG can revoke or modify an opinion if facts change.
• Opinions apply only to the requesting party; they are not precedential for other parties.
• The OIG charges a user fee plus OIG actual costs; consult the current OIG advisory-opinion application instructions at oig.hhs.gov for the fee structure and typical processing time before submitting.

Activity Levels

The OIG issues advisory opinions on an ongoing basis. Public versions of opinions (with confidential information redacted) are available at oig.hhs.gov. The opinions provide important guidance for the healthcare industry on common arrangement types.

The OIG Self-Disclosure Protocol

Background

The OIG Self-Disclosure Protocol (SDP) was established in 1998 and has been updated multiple times. The SDP allows healthcare providers to self-disclose actual or potential AKS, Civil Monetary Penalty Law, and other fraud violations to the OIG.

How SDP Works

A provider submits a disclosure to the OIG including:

• Description of the arrangement and potential violation.
• Legal analysis identifying the laws potentially violated.
• Description of the impact on federal healthcare programs.
• Calculation of single damages and proposed multiplier.
• Description of remedial actions taken.
• Compliance program enhancements.

Resolution Framework

OIG typically resolves SDP matters at a multiplier of single damages (refer to the current SDP guidance at oig.hhs.gov for the published baseline multiplier), often with a Corporate Integrity Agreement (CIA). Compared to the potential treble damages and per-claim penalties under the False Claims Act, SDP resolution provides substantial savings and certainty.

Coordination with Department of Justice

The OIG coordinates SDP matters with the DOJ Civil Frauds Section. Some SDP matters are resolved jointly with DOJ in False Claims Act settlements. The 2020 update to SDP refined the coordination process.

Corporate Integrity Agreements

A Corporate Integrity Agreement (CIA) is a multi-year compliance agreement that often accompanies AKS settlements. CIAs are required for many significant AKS resolutions.

CIA Components

• Multi-year term (commonly several years).
• Compliance officer with specific responsibilities.
• Code of conduct.
• Compliance training program.
• Internal monitoring and auditing program.
• Independent Review Organization (IRO) oversight.
• Reporting obligations to OIG.
• Annual reports.
• Disclosure requirements.

CIA Impact

CIAs substantially increase compliance costs and operational burden. Many healthcare entities prioritize avoiding CIA requirements through careful compliance program design and early issue identification. The CIA registry is publicly available at oig.hhs.gov.

The Beneficiary Inducement Civil Monetary Penalty

Section 1128A(a)(5)

Section 1128A(a)(5) of the Social Security Act prohibits a person from offering or transferring remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary's selection of a particular provider, practitioner, or supplier. The CMP carries a substantial per-item or per-service penalty (subject to annual inflation adjustment; check the current OIG CMP table for the current dollar amount).

Section 1128A(i)(6) Remuneration Exceptions

Section 1128A(i)(6) provides exceptions to the beneficiary inducement CMP definition of remuneration:

(A) Waivers of Coinsurance and Deductibles: Certain waivers for inpatient hospital services meeting specific criteria.

(B) Differential Cost-Sharing: Cost-sharing differentials offered by health plans (e.g., HMOs).

(C) Incentives to Promote Delivery of Preventive Services: Certain incentives for preventive care.

(D) Remuneration Not Likely to Influence Selection: Items or services of nominal value (consult the current OIG policy statement on nominal-value gifts for the current per-item and aggregate annual ceilings).

(E) Items and Services Promoting Access to Care: Added by the ACA, this exception allows certain remuneration that promotes access to care and poses low risk of program harm. The 2016 OIG rulemaking provided detailed guidance.

(F) Retailer Rewards Programs: Certain retailer rewards programs.

(G) Financial Need-Based Programs: Items and services provided to financially needy beneficiaries meeting specific criteria.

Promoting Access to Care Exception

The promoting-access-to-care exception is particularly important and was clarified by the ACA. The exception requires:

• The remuneration promotes access to care.
• The remuneration poses a low risk of harm to patients and federal healthcare programs.
• The remuneration is reasonably connected to the care being promoted.

Examples include transportation assistance, food vouchers, and other access-related supports.

The Eliminating Kickbacks in Recovery Act of 2018

Background

Section 220 of the SUPPORT Act of 2018 (Public Law 115-271), titled the Eliminating Kickbacks in Recovery Act (EKRA), extends AKS-like prohibitions to substance use disorder treatment beyond federal healthcare programs.

EKRA Coverage

EKRA prohibits knowing and willful payment of remuneration:

• To induce referrals for services from clinical laboratories.
• To induce referrals to recovery homes.
• To induce referrals to clinical treatment facilities (substance use disorder).

The prohibition applies regardless of payor (commercial, federal program, self-pay).

EKRA Safe Harbors

EKRA includes a separate set of safe harbors for arrangements not violating the law. Some EKRA safe harbors parallel AKS safe harbors; others are EKRA-specific.

EKRA Penalties

EKRA carries significant imprisonment exposure and a substantial fine per violation; confirm the current statutory maximums in 18 U.S.C. 220 as in effect today. EKRA is enforced by the Department of Justice.

EKRA Impact

EKRA has substantially affected clinical laboratory marketing arrangements, substance use disorder treatment marketing, and related industries. Many laboratory marketing arrangements that were permissible for commercial payors before EKRA are now potentially criminal.

Major AKS Enforcement Trends

Pharmaceutical Manufacturer Settlements

Pharmaceutical manufacturers have repeatedly settled large federal cases involving AKS allegations bundled with off-label marketing, often for sums in the hundreds of millions to billions of dollars. The DOJ press-release archive at justice.gov is the authoritative source for the specific dollar figures and dates of these settlements; pull the current list before citing any particular case.

OIG Special Fraud Alert on Speaker Programs (2020)

In November 2020, the OIG issued a Special Fraud Alert on pharmaceutical speaker programs, identifying high-risk features including: lavish meals, expensive venues, large attendee numbers, large speaker fees, audience composition (speakers' regular referral partners), use of speaker programs to provide remuneration to high-prescribing physicians, and absence of educational substance. Many pharmaceutical manufacturers substantially reduced or eliminated speaker programs following the alert.

Specialty Pharmacy and PBM Enforcement

The OIG and DOJ have pursued multiple specialty pharmacy and pharmacy benefit manager AKS cases, including allegations of:

• Payments to drug manufacturers in exchange for preferred formulary placement.
• Payments to providers for referring patients to specific specialty pharmacies.
• Rebate retention schemes.

Hospice and Home Health Enforcement

Hospice and home health agencies have been frequent AKS enforcement targets, including allegations of:

• Payments to nursing facilities or assisted living facilities for resident referrals.
• Marketing arrangements with physicians referring patients.
• Patient recruiter payments.

Device Manufacturer Enforcement

Medical device manufacturers have faced AKS enforcement related to:

• Royalty payments to physicians.
• Consulting fees beyond fair market value.
• Speaker programs (similar to pharmaceutical concerns).
• Surgeon preference items and competitive arrangements.

The Georgia AKS Enforcement Landscape

Federal Enforcement in Georgia

• U.S. Attorney's Office, Northern District of Georgia (Atlanta): The Northern District handles the most AKS enforcement actions in Georgia, given the metro Atlanta population concentration and major healthcare entity presence.
• U.S. Attorney's Office, Middle District of Georgia (Macon): Covers central Georgia.
• U.S. Attorney's Office, Southern District of Georgia (Savannah): Covers southern and coastal Georgia.
• OIG Atlanta Regional Office: OIG investigative office covering Georgia and other Southeast states.
• DEA Atlanta Field Division: Drug diversion and substance use disorder enforcement.
• FDA Office of Criminal Investigations: Drug and device manufacturer enforcement.
• DOJ Civil Frauds Section: Coordinates major FCA cases.

State Enforcement in Georgia

• Georgia Medicaid Fraud Control Unit (GMFCU): Operated by the Georgia Bureau of Investigation, GMFCU investigates and prosecutes Medicaid fraud.
• Georgia Attorney General's Office: Coordinates state Medicaid fraud and abuse cases.

Major Georgia Healthcare Entities and AKS Compliance

Georgia's major health systems (Emory Healthcare, Wellstar Health System, Piedmont Healthcare, Northside Hospital, Augusta University Health), large physician groups, specialty pharmacies, and pharmaceutical and device manufacturers maintain detailed AKS compliance programs. Common compliance areas include:

• Physician compensation arrangements
• Hospital-physician joint ventures
• Medical director and consulting agreements
• Recruitment arrangements
• Marketing and patient acquisition activities
• Beneficiary cost-sharing programs
• Pharmaceutical and device manufacturer interactions
• Specialty pharmacy arrangements

Worked Example 1: Hospital-Physician Joint Venture AKS Compliance

Scenario: A Georgia hospital and a cardiology group are forming a joint venture to operate a freestanding ambulatory surgery center for cardiac procedures. The joint venture includes hospital and physician ownership.

AKS Analysis:

• The hospital and physicians have a financial relationship through joint ownership.
• The physician owners will refer Medicare patients to the joint venture ASC for cardiac procedures.
• The relationship between ownership returns and physician referrals is the key AKS concern.

Safe Harbor Analysis:

• 42 CFR 1001.952(q) Ambulatory Surgical Centers safe harbor provides protection for certain ASC investment arrangements.
• Specific requirements: terms of investment, returns based on capital contribution not referrals, surgeon investor practice-test compliance, written investment documents, public disclosure to patients.

Documentation Required:

• ASC operating agreement.
• Surgeon investor agreements.
• Practice-test compliance documentation per the safe harbor's surgeon-investor procedure requirement.
• Investment returns based on capital not referrals.
• Patient disclosure documents.

Intent Analysis (If Safe Harbor Not Met):

• Are returns proportional to capital investment?
• Are returns disproportionate to investors who refer more?
• What are the parties' history and relationships?
• Is there commercial rationale beyond referrals?

Outcome: The arrangement can comply with AKS through the ASC safe harbor if all technical requirements are met, or through intent-based analysis if structured to remove referral-based remuneration considerations.

Worked Example 2: Pharmaceutical Manufacturer Speaker Program AKS Analysis

Scenario: A pharmaceutical manufacturer markets an oncology drug to Georgia physicians. The company maintains a speaker program where high-prescribing oncologists are paid speaker fees to present educational programs to peers.

AKS Analysis:

• The manufacturer is paying physicians (remuneration).
• The physicians prescribe the manufacturer's drugs (referrals/orders).
• The question is whether at least one purpose of the speaker fees is to induce prescribing.

OIG Special Fraud Alert on Speaker Programs (November 2020):

High-risk features identified:

• Lavish meals during speaker events.
• Expensive venues.
• Speakers paid substantial fees.
• Programs attended primarily by speakers' regular referral partners.
• Speakers selected based on prescribing volume.
• Lack of educational substance.
• Repetition of same programs to same audiences.
• Speaker programs offered to specialties unlikely to prescribe the drug.

Compliance Approach:

• Educational substance over entertainment.
• Speaker fees at fair market value.
• Diverse audience.
• Educational rather than marketing focus.
• Documented selection criteria not based on prescribing.

Outcome: Speaker programs can be structured to comply with AKS but face substantial scrutiny. Many pharmaceutical manufacturers reduced or eliminated speaker programs following the 2020 fraud alert.

Worked Example 3: Specialty Pharmacy Referral Arrangement

Scenario: A Georgia health system operates a specialty pharmacy and physician practices that prescribe specialty drugs. The health system would like to direct prescriptions from its employed physicians to its specialty pharmacy.

AKS Analysis:

• The specialty pharmacy and prescribing physicians are owned by the same entity (the health system).
• The physicians are employees of the health system.
• The Employee safe harbor (42 CFR 1001.952(i)) provides broad protection for bona fide employment relationships.
• Internal direction of prescriptions to the health system's specialty pharmacy is generally permitted, with appropriate patient choice protections.

Compliance Considerations:

• Patient choice: Patients retain the right to use other specialty pharmacies.
• Employment compensation must be FMV and not based on referral volume to specialty pharmacy.
• Documentation of employment relationship and compensation methodology.

Outcome: Internal specialty pharmacy direction can comply with AKS through the employee safe harbor, with appropriate patient choice and FMV employment compensation.

Contrast with External Arrangements: If the specialty pharmacy paid referring physicians outside the same entity for referrals, the arrangement would face significant AKS exposure absent specific safe harbor compliance.

Worked Example 4: Beneficiary Cost-Sharing Waiver CMP Analysis

Scenario: A Georgia oncology practice routinely waives the Part B coinsurance for Medicare beneficiaries who cannot afford it, without conducting individualized financial need assessments.

CMP Analysis:

• Routine waiver of coinsurance constitutes remuneration under Section 1128A(a)(5).
• The waiver is likely to influence beneficiary selection of the practice (beneficiary inducement).
• CMP exposure per item or service applies.

Section 1128A(i)(6) Exception Analysis:

• The promoting-access-to-care exception (added by ACA) may apply if specific requirements are met.
• Requires: (1) remuneration promotes access to care; (2) poses low risk of harm; (3) reasonably connected to care.
• Routine waivers without financial need assessment generally do not qualify.

Compliance Approach:

• Individualized financial need assessment (income, assets).
• Documented financial hardship determination.
• Application of consistent financial hardship policy.
• Documented inability of beneficiary to pay.

Alternative Compliance Approaches:

• Foundation co-pay assistance (third-party charitable assistance).
• Manufacturer patient assistance programs.
• Internal hospital financial assistance with documented hardship.

Outcome: Individualized financial hardship waivers can comply with CMP requirements; routine waivers generally do not.

Worked Example 5: EHR Donation Safe Harbor Compliance

Scenario: Wellstar Health System wishes to donate Epic EHR software and implementation services to a community physician practice that refers patients to Wellstar hospitals.

AKS Analysis:

• Wellstar is providing remuneration (EHR software and services) to physicians.
• The physicians refer patients to Wellstar (referrals).
• The 42 CFR 1001.952(y) EHR donation safe harbor may apply.

Safe Harbor Requirements:

1. Recipient must pay a meaningful share of the donor's cost (verify the current cost-sharing percentage in 42 CFR 1001.952(y) as in effect today).
2. Items and services must be primarily used for healthcare delivery.
3. Software must be interoperable per ONC standards.
4. Recipient must not be required to make referrals.
5. Written agreement covering the donation.
6. Anti-information-blocking provisions.
7. Other specific requirements.

Documentation Required:

• Written EHR donation agreement.
• Physician cost-share payment per the safe harbor's current percentage.
• Interoperability compliance documentation.
• Anti-information-blocking provisions.

Coordination with Stark Law:

• 42 CFR 411.357(w) Stark EHR donation exception parallels the AKS safe harbor.
• Most arrangements analyzed under both simultaneously.

Outcome: The arrangement can comply with AKS through the EHR donation safe harbor if all technical requirements are met.

Worked Example 6: Hospice Marketing Arrangement AKS

Scenario: A Georgia hospice provider operates a marketing program where representatives visit assisted living facilities and nursing facilities to discuss hospice services. The hospice provides educational materials, in-services for facility staff, and other support.

AKS Analysis:

• The hospice is providing remuneration (in-services, support) to facilities.
• The facilities refer patients to the hospice (referrals).
• The question is whether the support is intended to induce referrals.

Compliance Considerations:

• Educational substance vs marketing emphasis.
• Fair market value of in-services if compensated.
• Absence of referral-volume incentives.
• Compliance with OIG hospice compliance program guidance.
• Documentation of educational purpose.

High-Risk Features (Per OIG):

• Providing free services beyond educational value.
• Compensating facility staff for referrals.
• Providing equipment or amenities to facilities.
• Excessive marketing expenditures.

Outcome: Hospice marketing can be structured to comply with AKS through emphasis on educational rather than remunerative features. The OIG has issued multiple hospice fraud alerts identifying high-risk features.

Best Practices for Georgia Healthcare Entities

1. Maintain a comprehensive AKS compliance program: Include written policies, training, regular audits, hotline, compliance officer reporting to board, code of conduct, and disciplinary standards. OIG industry-specific compliance program guidance provides detailed frameworks.

2. Map all financial relationships: Maintain an inventory of all written agreements, payments, in-kind benefits, and other relationships involving physicians and other referral sources.

3. Document fair market value: Obtain independent FMV documentation for all material physician compensation and vendor arrangements. Update FMV assessments annually or when arrangements change.

4. Document commercial reasonableness: For each arrangement, document the business rationale and how the arrangement makes sense independent of referrals.

5. Use safe harbors when possible: Structure arrangements to fit within applicable safe harbors when feasible. Document compliance with each technical requirement.

6. Apply intent-based analysis when outside safe harbors: For arrangements that do not fit safe harbors, document the intent analysis and risk-mitigating features.

7. Consider OIG advisory opinion for unusual arrangements: For novel or particularly complex arrangements, consider seeking an OIG advisory opinion for legal certainty.

8. Use SDP when violations are identified: When internal investigations identify AKS violations, evaluate Self-Disclosure Protocol submission. Engage experienced healthcare regulatory counsel.

9. Train all relevant personnel: AKS training should include physicians, sales representatives, contracting staff, finance personnel, and senior leaders. Document training completion.

10. Coordinate AKS and Stark analysis: Most arrangements implicate both laws. Use coordinated compliance review processes.

11. Maintain marketing compliance: Marketing and patient acquisition activities require detailed AKS compliance review, particularly for hospice, home health, specialty pharmacy, and other industries with elevated risk profiles.

12. Implement beneficiary inducement controls: Beneficiary cost-sharing waiver and patient assistance programs require careful structuring to avoid CMP issues.

13. Conduct M&A AKS due diligence: When acquiring healthcare entities, conduct thorough AKS due diligence including review of relationships, vendor arrangements, marketing programs, and patient programs.

14. Monitor regulatory developments and Special Fraud Alerts: OIG continues to issue alerts, advisory opinions, and rulemakings. Maintain awareness of developments affecting your operations.

Common Issues and How to Address Them

1. Above-FMV physician compensation: When physician compensation exceeds FMV ranges, AKS and Stark exposure grows. Solution: Annual FMV reviews; adjustment to FMV; or SDP if past violations identified.

2. Marketing arrangements with referral sources: Marketing relationships with potential referral sources (e.g., hospice marketing to facilities, specialty pharmacy marketing to physicians) require detailed AKS analysis. Solution: Structure as educational rather than promotional; FMV pricing for any services provided; absence of referral-based metrics.

3. Speaker program structure: Pharmaceutical and device speaker programs face substantial scrutiny since OIG's 2020 Special Fraud Alert. Solution: Educational substance, FMV speaker fees, diverse audiences, documented selection criteria.

4. Routine cost-sharing waivers: Routine waivers of beneficiary cost-sharing without financial need assessment violate CMP requirements. Solution: Individualized financial hardship determinations; third-party foundation assistance.

5. Above-FMV vendor arrangements: Vendor arrangements with referral-source customers (e.g., a hospital that purchases services from a physician-owned vendor) require FMV documentation. Solution: Independent FMV analysis; competitive bidding processes.

6. EHR donation cost-sharing: Failure to collect the required physician cost share violates the EHR safe harbor. Solution: Implement collection processes; document payments per the current safe harbor percentage.

7. Free or below-cost services to referral sources: Providing services below cost or free to referral sources can constitute remuneration. Solution: FMV pricing; commercial reasonableness documentation.

8. Investment arrangement violations: Physician ownership in entities providing services to their patients raises AKS concerns. Solution: Investment safe harbor compliance (ASC, group practice, etc.); appropriate structure.

9. Patient navigator and care coordinator arrangements: Patient support services can implicate AKS depending on structure. Solution: Care coordination safe harbor (2020 rule); appropriate structure.

10. Specialty pharmacy referral arrangements: External specialty pharmacy referral arrangements face AKS exposure. Solution: Employee safe harbor for internal arrangements; specific safe harbor analysis for external.

11. Joint venture distributions: Joint venture distributions disproportionate to capital investment raise AKS concerns. Solution: Distributions based on capital not referrals; ASC or other applicable safe harbor.

12. Recruitment payment compliance: Hospital recruitment payments must meet specific safe harbor or Stark exception requirements. Solution: Practitioner recruitment safe harbor (42 CFR 1001.952(m)); careful documentation.

13. EKRA implications for laboratory marketing: Laboratory marketing arrangements face EKRA exposure beyond traditional AKS. Solution: EKRA safe harbor analysis; restructure as needed.

14. Telehealth arrangements: Telehealth raises new AKS questions. Solution: Specific analysis under existing safe harbors; monitor OIG telehealth guidance.

A few more common questions:

How does the AKS apply to pharmaceutical speaker programs? Pharmaceutical speaker programs (where physicians are paid speaker fees to present educational programs) face substantial AKS scrutiny. The OIG's November 2020 Special Fraud Alert on speaker programs identified high-risk features including lavish meals, expensive venues, large speaker fees, audiences of speakers' regular referral partners, speakers selected based on prescribing volume, and absence of educational substance. Many pharmaceutical manufacturers substantially reduced or eliminated speaker programs after the alert.

How does the AKS apply to hospital-physician joint ventures? Hospital-physician joint ventures (ASCs, imaging centers, dialysis facilities) face detailed AKS analysis. The 42 CFR 1001.952(q) ambulatory surgical center safe harbor provides specific protection for ASC arrangements meeting requirements including investment terms, returns based on capital not referrals, practice tests for surgeon investors, and patient disclosure. Other joint ventures may rely on different safe harbors or intent-based analysis.

How does the AKS apply to hospice marketing? Hospice marketing has been a frequent AKS enforcement target. High-risk features identified by OIG include payments to nursing facilities or assisted living facilities for resident referrals, compensation to facility staff for referrals, and excessive marketing expenditures to potential referral sources. Hospice marketing should emphasize educational substance over promotional activities, with all support to facilities at fair market value and without referral-based metrics.

How does the AKS apply to specialty pharmacy? Specialty pharmacy arrangements face AKS scrutiny when there are payment arrangements between the pharmacy and external referral sources. Internal direction of prescriptions within an integrated health system (where physicians are employees and direct to the system's specialty pharmacy) is generally protected by the employee safe harbor with appropriate patient choice protections.

How does the AKS apply to EHR donations? 42 CFR 1001.952(y) EHR Items and Services safe harbor protects EHR donation arrangements meeting specific requirements: recipient pays a meaningful share of donor cost, software is interoperable per ONC standards, recipient not required to refer, written agreement, anti-information-blocking provisions, primarily used for healthcare delivery, and other specific requirements. The safe harbor parallels the Stark Law EHR donation exception at 42 CFR 411.357(w).

What is the OIG Self-Disclosure Protocol? The OIG Self-Disclosure Protocol, established in 1998 and updated multiple times, allows healthcare providers to self-disclose AKS, Civil Monetary Penalty Law, and other fraud violations for resolution at less than the full statutory penalty. Compared to potential FCA treble damages and per-claim penalties, SDP provides substantial savings and certainty.

What is the False Claims Act connection? Section 6402(f) of the ACA established that AKS violations constitute per se false claims under the federal False Claims Act (31 U.S.C. 3729-3733). This eliminates the need for prosecutors and qui tam relators to separately establish a false-statement connection. FCA penalties include treble damages plus per-claim civil penalties indexed annually for inflation.

Where can Georgia healthcare entities get AKS compliance assistance? Georgia healthcare entities can engage experienced healthcare regulatory attorneys at firms including Alston & Bird, King & Spalding, Bryan Cave Leighton Paisner, McGuireWoods, Hall Booth Smith, and others. The Georgia Hospital Association provides member resources. The State Bar of Georgia Health Law Section offers continuing education. OIG resources are available at oig.hhs.gov, including the Advisory Opinion database, Self-Disclosure Protocol, Special Fraud Alerts, and Compliance Program Guidance.

Brevy: Your Partner in Navigating Healthcare Compliance

At Brevy (brevy.com), our mission is to provide Georgia families and the broader Georgia healthcare community with comprehensive, up-to-date guidance on Medicare, Medicaid, VA benefits, and the regulatory frameworks that shape eldercare delivery. The Anti-Kickback Statute affects virtually every aspect of Georgia healthcare operations, from how hospitals compensate physicians to how pharmaceutical manufacturers interact with prescribers to how hospice providers market their services. While Medicare beneficiaries do not typically interact with AKS compliance directly, the law's framework determines how Georgia healthcare entities structure their relationships, which in turn affects the availability, integration, and pricing of healthcare services across the state.

If you are a Georgia healthcare administrator, compliance professional, physician practice manager, or healthcare attorney navigating AKS compliance, please engage qualified healthcare regulatory counsel for arrangement-specific guidance and consult the resources listed below.

Find personalized help navigating Georgia healthcare compliance at brevy.com.